VEXAS
Clinical trials for VEXAS explained in plain language.
Never miss a new study
Get alerted when new VEXAS trials appear
Sign up with your email to follow new studies for VEXAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug pacritinib takes aim at rare inflammatory VEXAS syndrome
Disease control Recruiting nowThis phase 1 trial tests the safety and tolerability of pacritinib, a pill that blocks JAK2 and IRAK1, in people with VEXAS syndrome—a rare, severe autoinflammatory disorder caused by a UBA1 gene mutation. Up to 15 participants will take pacritinib daily for up to 12 cycles, star…
Matched conditions: VEXAS
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for rare inflammatory disease: pacritinib trial begins
Disease control Recruiting nowThis study tests a drug called pacritinib for people with VEXAS syndrome, a rare genetic disease that causes severe inflammation. About 78 adults will receive either the drug or a placebo to see if it controls symptoms and reduces flare-ups. The goal is to find a safe and effecti…
Matched conditions: VEXAS
Phase: PHASE2 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC